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Introduction: Pleural effusion is frequently observed in patients 
with advanced lung cancer. Although effusion can be obtained less 
invasively and repeatedly, its use in multiplexed molecular profiling 
has not been fully investigated.
Methods: Between July 2011 and April 2013, pleural effusion sam-
ples were obtained from patients with lung cancer at Shizuoka Cancer 
Center. They were analyzed for EGFR, KRAS, BRAF, PIK3CA, 
NRAS, MEK1, AKT1, PTEN, and HER2 mutations, EGFR, MET, 
FGFR1, FGFR2, and PIK3CA amplifications, and ALK, ROS1, and 
RET fusion genes using pyrosequensing and/or capillary electropho-
resis, quantitative reverse-transcriptase polymerase chain reaction, 
and reverse-transcriptase polymerase chain reaction, respectively.
Results: One hundred and two samples from 84 patients were ana-
lyzed. Adenocarcinoma was the most common histological subtype 
(82%). Genetic abnormalities were detected in 42% of patients. The 
most common abnormality was EGFR mutation (29%), followed by 
EML4-ALK rearrangement (5%), KRAS mutation, and EGFR ampli-
fication (4%, each). Concordance rates between pleural effusion 
and matched formalin-fixed, paraffin-embedded samples were 88%. 
Among 11 patients who provided samples at multiple time points, 
changes in molecular profile over the course of treatment were 
observed in five patients.
Conclusions: The use of pleural effusion for multiplexed molecular 
testing and real-time monitoring in lung cancer was demonstrated.
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Development of molecular cancer therapeutics has brought numerous benefits to patients with driver mutations. 
Non–small-cell lung cancer (NSCLC) is one of such malig-
nancies with targetable genetic alterations. In NSCLC patients 
who harbor epidermal growth factor receptor (EGFR) muta-
tion, EGFR-tyrosine kinase inhibitors double progression-free 
survival compared with platinum containing chemotherapy.1 
In 2007, anaplastic lymphoma kinase (ALK) rearrangement 
was discovered in approximately 5% of NSCLC,2 and ALK 
inhibitor (crizotinib) was rapidly approved in 5 years, both 
in the United States and Japan. Today, druggable oncogenes 
other than EGFR and ALK have been detected,3,4 and develop-
ment of specific inhibitors is underway.
In the era of multiplexed molecular profiling, tumors 
should be tagged with some genetic abnormalities before 
treatment. To detect such abnormalities, an ample yield of 
tumor cells is necessary. Among lung cancer patients, pleu-
ral effusion is observed in 7–15%,5 and it can be obtained 
less invasively and repeatedly compared with primary lesion. 
Although pleural effusion is a potential candidate for molecu-
lar testing, its use in multiplexed molecular profiling has not 
been fully investigated.
In July 2011, we started the ‘‘Shizuoka lung cancer 
mutation study,’’ a prospective tumor genotyping study of 
patients with thoracic malignancies. Using these samples, we 
conducted a multiplexed molecular profiling of advanced lung 
cancer with pleural effusion.
MATERIALS AND METHODS
Patient Selection and Samples
Between July 2011 and April 2013, consecutive 
patients with pathologically confirmed lung cancer at 
Shizuoka Cancer Center were enrolled in the ‘‘Shizuoka 
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lung cancer mutation study’’. Written informed consent was 
obtained from all participants, and this study was approved 
by the institutional review board of our hospital. The diag-
nosis of the tumor was done by institutional pathologists in 
accordance with the 2004 World Health Organization clas-
sification. Pleural effusion samples of up to 250 ml were 
obtained at the time of diagnosis or therapeutic drainage. 
To analyze concordance rate of molecular profile between 
pleural effusion and tissue samples, formalin-fixed, paraffin-
embedded (FFPE) samples at the time of diagnosis were pro-
vided. Results of mutational testing were communicated to 
clinicians.
Molecular Analyses of Pleural 
Effusion and Tissue Samples
Cell isolation from pleural effusion was performed 
and sored at −80°C until use. Genomic DNAs were extracted 
using QIAamp DNA mini kit (QIAGEN, Hilden, Germany). 
From FFPE samples, DNAs were extracted using QIAamp 
DNA FFPE tissue kit (QAIGEN). DNA concentration was 
measured using Quant-iT PicoGreen dsDNA assay kit 
(Invitrogen, Carlsbad, CA). Total RNAs were extracted from 
pleural effusion with RNeasy Mini kit (QIAGEN) and mea-
sured by spectrophotometer (NanoDrop 2000C; Thermo 
Scientific, Wilmington, DE). They were analyzed for EGFR, 
KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, and 
HER2 mutations, EGFR, MET, FGFR1, FGFR2, and PIK3CA 
amplifications, and ALK, ROS1, and RET fusion genes using 
pyrosequensing and/or capillary electrophoresis, quantitative 
reverse-transcriptase polymerase chain reaction, (qRT-PCR) 
and RT-PCR, respectively (Tables 1 and 2). Each analyzing 
method is described in the Supplemental Digital Content 1 
(http://links.lww.com/JTO/A601).
Statistical Analysis
The primary purpose of this study was to explore the 
use of pleural effusion in multiplexed molecular profiling 
of advanced lung cancer. Detection rate was defined as the 
proportion of samples with genetic abnormalities. If multiple 
samples were obtained from the same patient, results for the 
first sample were adopted. Detection rate between the two 
groups (pathologically positive or negative) were analyzed 
using Fisher’s exact test. Concordance rate of molecular pro-
file between pleural effusion samples and matched FFPE sam-
ples were also analyzed. Probability values of < 0.05 indicated 
a statistically significant difference. All the analyses were per-
formed using JMP ver.7 (SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
Among 845 consecutive patients enrolled in the 
‘‘Shizuoka lung cancer mutation study’’ during the study 
period, pleural effusion samples were obtained from 92 
patients. Eight patients were ineligible because further inves-
tigations indicated that they did not have lung cancer (three 
non-thoracic malignancies, one incidence each of malignant 
pleural mesothelioma, invasive thymoma, thymic carcinoma, 
tracheal carcinoma, and spindle cell sarcoma). Then, 102 sam-
ples from 84 patients were analyzed (Fig. 1).
Patient characteristics are summarized in Table 3. 
Median age was 69 (range 29–85), 69% were male, 63% were 
current smokers, and the most common histology was adeno-
carcinoma (82%). Forty-three samples (42%) were obtained 
at the time of initial diagnosis. In 11 patients (13%), samples 
were obtained at multiple time points.
Detection of Genetic Abnormalities
Genetic abnormalities were detected in 35 patients 
(42%; 95% confidence interval: 31–52%). In 80 patients, 
TABLE 1.  Multiple Tumor Genotyping Panel
Mutations
Gene Position AA Mutant
Nucleotide 
Mutant
EGFR G719 G719C/S 2155G>T/A
G719A 2156G>C
exon 19 Deletion
T790 T790M 2369C>T
exon 20 Insertion
L858 L858R 2573T>G
L861 L861Q 2582T>A
KRAS G12 G12C/S/R 34G>T/A/C
G12V/A/D 35G>T/C/A
G13 G13C/S/R 37G>T/A/C
G13D/A 38G>A/C
Q61 Q61K 181C>A
Q61R/L 182A>G/T
Q61H 183A>T/C
BRAF G466 G466V 1397G>T
G469 G469A 1406G>C
L597 L597V 1789C>G
V600 V600E 1799T>A
PIK3CA E542 E542K 1624G>A
E545 E545K/Q 1633G>A/C
H1047 H1047R 3140A>G
NRAS Q61 Q61K 181C>A
Q61L/R 182A>T/G
MEK1 (MAP2K1) Q56 Q56P 167A>C
K57 K57N 171G>T
D67 D67N 199G>A
AKT1 E17 E17K 49G>A
PTEN R233 R233* 697C>T
HER2 Exon 20 Insertion
TABLE 2.  Amplifications and Fusion Genes
Gene Amplifications Fusion Genes
EGFR EML4-ALK
MET CD74-ROS1
PIK3CA SLC34A2-ROS1
FGFR1 KIF5B-RET
FGFR2 CCDC6-RET
1050 Copyright © 2014 by the International Association for the Study of Lung Cancer
Akamatsu et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014
samples were divided into aliquots and reviewed by institu-
tional pathologist. Among 63 samples that were pathologically 
positive, genetic abnormalities were detected in 30 samples. 
On the other hand, among 17 samples that were pathologically 
negative, abnormalities were detected only in three samples. 
There was a significant difference in detection rate (48% ver-
sus 18%, p = 0.03, Fig. 2).
The most common abnormality was EGFR mutation (24 
patients; Fig. 3). Other abnormalities were as follows; EML4-
ALK rearrangement (four patients), KRAS mutation, and 
EGFR amplification (three patients, each), PIK3CA mutation, 
and MET amplification (two patients), BRAF mutation, NRAS 
mutation, AKT mutation, ROS1 fusion, and FGFR1 amplifica-
tion (one patient, each). Seven patients had multiple genetic 
alterations simultaneously. The concordance rates between 
pleural effusion and matched FFPE samples were 88%.
Among 11 patients who provided samples at multiple 
time points, changes in molecular profiles over the course of 
treatment were observed in five patients (Table 4). Three har-
bored EGFR-sensitive mutations, and two had ALK rearrange-
ment in the first analysis. After EGFR-tyrosine kinase inhibitor 
(TKI) administration, EGFR-mutated patients acquired addi-
tional mutation (exon 20 T790M mutation). Erlotinib was 
started in one patient (no. 3), but she progressed in 3 weeks. 
In ALK rearranged patients, ALK fusion gene disappeared 
after crizotinib exposure. In one patient (no. 5), ALK fusion 
gene was detected again in third sample. He was treated with 
another ALK inhibitor, and it shrinked his tumor for 7 months.
DISCUSSION
Sequist et al. reported a multiplexed PCR-based geno-
typing system for NSCLC.6 They extracted DNA from FFPE 
specimens that were prescreened by a pathologist. They dem-
onstrated that half of patients had greater than or equal to one 
genetic abnormality. However, adequate tissue is difficult to 
obtain from advanced lung cancer patients. Tissue accrual 
rates in pivotal studies of NSCLC were only approximately 
20%.7 Thus, cytology samples occupy a substantial position in 
molecular testing today. Pleural effusion is a potential candi-
date because it can be obtained less invasively and repeatedly. 
In EGFR mutation testing, several studies have demonstrated 
the use of pleural effusion.8,9 In this study, we aimed to get 
one step further and explored multiplexed molecular profiling 
using pleural effusion and achieved a comparable detection 
rate (42%) to Sequist’s analysis with FFPE samples.
Our analysis teaches the importance of screening malig-
nant cells by pathologists before genetic testing. However, 
the 18% detection rate shown in samples without malignant 
cells should not be considered negligible. Buttitta et al.11 ana-
lyzed effusion samples with few or no malignant cells using 
direct sequencing and next generation sequencing (NGS).10 
Surprisingly, NGS detected EGFR mutation in 42% of sam-
ples without malignant cells, whereas direct sequencing could 
not detect any mutation. Pathologically positive samples 
contain at least 1% cancer cells, in general. Buttitta et al.’s11 
data suggest that highly sensitive methods may be superior to 
pathological diagnosis. Clinicians can try molecular profiling 
even with pathologically negative samples, if highly sensitive 
methods such as NGS and digital PCR are available.
FIGURE 1.  Flow chart of the patients analyzed in this study.
TABLE 3.  Baseline Characteristics
Characteristic N = 84
Age-year
  Median 69
  Range 29–85
Sex-no.(%)
  Male 58 (69)
  Female 26 (31)
Smoking status
  Never or light smoker 23 (27)
  Current smoker 61 (73)
Histology no.(%)
  Adenocarcinoma 69 (82)
  Squamous cell carcinoma 8 (10)
  Small cell carcinoma 7 (8)
FIGURE 2.  Proportion of samples with genetic abnormalities 
among whole population (N = 84), pathologically positive 
patients (N = 60), and pathologically negative patients  
(N = 17). In four patients, pathological diagnosis was 
not given.
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Even in a small subset, we demonstrated relatively 
higher concordance rates (88%) between pleural effusion and 
FFPE samples. This was comparable with Vignot’s report that 
demonstrated higher concordance rates (94%) using next gen-
eration sequencing between primary and matched metastatic 
samples obtained by surgery in 15 patients.11
At last, we could observe changes of molecular profile 
over the course of treatment in five patients. Such a monitor-
ing strategy of molecular profiling was already attempted in 
metastatic breast cancer.12 Among EGFR-mutated lung cancer 
patients, Sequiest et al. reported the mechanism of resistance 
in detail.13 T790M mutation was the most common (49%), but 
MET, EGFR amplification, PIK3CA mutation, and transfor-
mation to small cell lung cancer were also observed. To choose 
subsequent therapy, identifying these molecular changes may 
provide some help.
Our analysis has some limitations. First of all, our study 
contained various types of lung cancer. Second, the timing of 
effusion samples obtainment and their volume depended on 
investigators’ discretion. Therefore, our detection rate of ours 
should be interpreted cautiously.
In conclusion, this is the first report to investigate the 
use of pleural effusion using multiplexed molecular test-
ing in lung cancer. Our analysis was able to detect genetic 
abnormalities in 42% of samples, and concordance rates 
between pleural effusion and tissue samples were relatively 
high. In some cases, molecular profiles could be monitored 
with pleural effusion.
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FIGURE 3.  Relative frequency of 
genetic abnormalities analyzed from 
102 pleural effusion samples.
TABLE 4.  Details of Five Patients Who Provided Changes in Molecular Profile over the Courses of Treatment
NO.
Clinical 
Background
Molecular Profile of 
First Sample Treatment
Molecular Profile of 
Second Sample
Clinical Course After Second 
Sample
1 EGFR-TKI 
naïve
EGFR (L858R) Erlotinib EGFR (L858R  
+ T790M)
Best supportive care
2 EGFR-TKI 
naïve
EGFR (G719S) Gefitinib EGFR (G719S 
+ T790M)
Best supportive care
3 EGFR-TKI 
naïve
EGFR (exon19del) Gefitinib EGFR (exon19del  
+ T790M)
Erlotinib was not effective.
4 ALK-TKI 
naïve
EML4-ALK (v3a/3b) Crizotinib Not detected Crizotinib was not effective.
5 ALK-TKI 
naïve
EML4-ALK (v3a/3b) Crizotinib Not detected EML4-ALK(v3a/3b) was 
detected from third sample, 
and another ALK-TKI was 
effective.
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